OABI
OmniAb, Inc.
NASDAQ · USHealthcareBiotechnology
$2.08-1.89%
Price as of Jul 20, 2026
OABI growth
OmniAb, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +8.1%
- EBITDA
- +27.9%
- EBIT
- +18.2%
- EPS
- +20.7%
- Free cash flow
- +34.4%
- Operating cash flow
- +33.8%
Forward estimates
- Revenue
- +3.0%
- EBITDA
- +44.8%
- EPS
- +6.5%
Three-year CAGR
- Revenue
- -31.9%
- EBITDA
- +6.9%
- EBIT
- +4.0%
- Net income
- -4.4%
- EPS
- +6.6%
- Free cash flow
- +10.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.